Literature DB >> 21969507

Conditional probability of survival in patients with newly diagnosed glioblastoma.

Mei-Yin C Polley1, Kathleen R Lamborn, Susan M Chang, Nicholas Butowski, Jennifer L Clarke, Michael Prados.   

Abstract

PURPOSE: The disease outcome for patients with cancer is typically described in terms of estimated survival from diagnosis. Conditional probability offers more relevant information regarding survival for patients once they have survived for some time. We report conditional survival probabilities on the basis of 498 patients with glioblastoma multiforme receiving radiation and chemotherapy. For 1-year survivors, we evaluated variables that may inform subsequent survival. Motivated by the trend in data, we also evaluated the assumption of constant hazard. PATIENTS AND METHODS: Patients enrolled onto seven phase II protocols between 1975 and 2007 were included. Conditional survival probabilities and 95% CIs were calculated. The Cox proportional hazards model was used to evaluate prognostic values of age, Karnofsky performance score (KPS), and prior progression 1-year post diagnosis. To assess the constant hazard assumption, we used a likelihood-ratio test to compare the Weibull and exponential distributions.
RESULTS: The probabilities of surviving an additional year given survival to 1, 2, 3, and 4 years were 35%, 49%, 69%, and 93%, respectively. For patients who survived for 1 year, lower KPS and progression were significantly predictive of shorter survival (both P < .001), but age was not (hazard ratio, 1.22 for a 10-year increase; P = .25). The Weibull distribution fits the data significantly better than exponential (P = .02), suggesting nonconstant hazard.
CONCLUSION: Conditional probabilities provide encouraging information regarding life expectancy to survivors of glioblastoma multiforme. Our data also showed that the constant hazard assumption may be violated in modern brain tumor trials. For single-arm trials, we advise using individual patient data from historical data sets for efficacy comparisons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969507      PMCID: PMC3208537          DOI: 10.1200/JCO.2010.32.4343

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

1.  The conditional survival statistics for survivors with primary supratentorial astrocytic tumors.

Authors:  S L Hwang; Y H Yang; A S Lieu; M C Chuang; S J Chang; Y Y Chang; H J Lin; S L Howng
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

2.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

Authors:  James R Anderson; Kevin C Cain; Richard D Gelber
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

3.  A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.

Authors:  Nicholas Butowski; Michael D Prados; Kathleen R Lamborn; David A Larson; Patricia K Sneed; William M Wara; Mary Malec; Jane Rabbitt; Margaretta Page; Susan M Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

4.  The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data.

Authors:  F G Davis; B J McCarthy; S Freels; V Kupelian; M L Bondy
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

5.  Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Authors:  Michael D Prados; Susan M Chang; Nicholas Butowski; Rebecca DeBoer; Rupa Parvataneni; Hannah Carliner; Paul Kabuubi; Jennifer Ayers-Ringler; Jane Rabbitt; Margaretta Page; Anne Fedoroff; Penny K Sneed; Mitchel S Berger; Michael W McDermott; Andrew T Parsa; Scott Vandenberg; C David James; Kathleen R Lamborn; David Stokoe; Daphne A Haas-Kogan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

6.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.

Authors:  Susan M Chang; Kathleen R Lamborn; Mary Malec; David Larson; William Wara; Penny Sneed; Jane Rabbitt; Margaretta Page; M Kelly Nicholas; Michael D Prados
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-10-01       Impact factor: 7.038

8.  The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme.

Authors:  C L Lin; A S Lieu; K S Lee; Y H C Yang; T H Kuo; M H Hung; J K Loh; C P Yen; C Z Chang; S L Howng; S L Hwang
Journal:  Surg Neurol       Date:  2003-11

9.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

  9 in total
  25 in total

1.  Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008.

Authors:  Y Yuan; J Ross; Q Shi; F G Davis
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Evaluating patients for psychosocial distress and supportive care needs based on health-related quality of life in primary brain tumors: a prospective multicenter analysis of patients with gliomas in an outpatient setting.

Authors:  Anne-Katrin Hickmann; Marlene Hechtner; Minou Nadji-Ohl; Mareile Janko; Ann Katrin Reuter; Karoline Kohlmann; Markus Haug; Sonja Grüninger; Monika Deininger; Oliver Ganslandt; Jochem König; Christian Rainer Wirtz; Jan Coburger; Mirjam Renovanz
Journal:  J Neurooncol       Date:  2016-09-16       Impact factor: 4.130

Review 3.  Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Authors:  Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Journal:  Metab Brain Dis       Date:  2013-04-02       Impact factor: 3.584

4.  Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma.

Authors:  Y Zhu; Y P Hong; H L Zhang; G H Shi; W J Xiao; Z H Wang; X D Yao; S L Zhang; B Dai; D W Ye
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-29       Impact factor: 4.553

5.  Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

6.  Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

Authors:  So Young Ji; Jongjin Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong Hwy Kim; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Yongdai Kim; Chul-Kee Park
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

7.  Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000.

Authors:  Denice D Tsao-Wei; Jia Hu; Susan G Groshen; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

8.  Seizures during the management of high-grade gliomas: clinical relevance to disease progression.

Authors:  Young-Hoon Kim; Chul-Kee Park; Tae Min Kim; Seung Hong Choi; Yu Jung Kim; Byung Se Choi; Jung Ho Han; Se-Hoon Lee; Chae-Yong Kim; In Ah Kim; Dae Seog Heo; Il Han Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

9.  Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Caroline Chung; Barbara-Ann Millar; Arjun Sahgal; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-29       Impact factor: 4.130

10.  Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012.

Authors:  Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-04-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.